Search results
AbCellera Biologics (ABCL) Upgraded to Buy: Here's What You Should Know
Zacks via Yahoo News· 1 day agoAbCellera Biologics (ABCL) might move higher on growing optimism about its earnings prospects, which...
Redfin (RDFN) Upgraded to Buy: Here's What You Should Know
Zacks via Yahoo News· 1 day agoRedfin (RDFN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2...
C4 Therapeutics (CCCC) Upgraded to Buy: Here's Why
Zacks via Yahoo News· 1 day agoC4 Therapeutics, Inc. (CCCC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a...
Jack Henry (JKHY) Upgraded to Buy: What Does It Mean for the Stock?
Zacks via Yahoo News· 1 day agoJack Henry (JKHY) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2...
What Makes Teleflex (TFX) a New Buy Stock
Zacks via Yahoo News· 1 day agoTeleflex (TFX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of...
Century Therapeutics (IPSC) Moves to Buy: Rationale Behind the Upgrade
Zacks via Yahoo News· 1 day agoCentury Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects,...
Norwegian Cruise Line (NCLH) Moves to Buy: Rationale Behind the Upgrade
Zacks via Yahoo News· 1 day agoNorwegian Cruise Line (NCLH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism...
What Makes Curis (CRIS) a New Buy Stock
Zacks via Yahoo News· 1 day agoCuris (CRIS) appears an attractive pick, as it has been recentlyupgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the...
What Makes Staffing 360 (STAF) a New Buy Stock
Zacks via Yahoo News· 1 day agoStaffing 360 (STAF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the...
Beam Therapeutics (BEAM) Upgraded to Buy: What Does It Mean for the Stock?
Zacks via Yahoo News· 1 day agoBeam Therapeutics (BEAM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism...